The OncLive® Sponsored section encompasses all sponsored content that is presented as articles, video interviews, webinars, blog posts, and more across various types of malignancies, including breast cancer, lung cancer, hematologic cancers, gynecologic cancers, gastrointestinal cancers, genitourinary cancers, and more.
Our ambition is to outsmart cancer by translating our science into health. The combination of our people and heritage is a particular advantage we have in achieving this goal. Our teams are curious, bold, and driven to deliver potentially transformative medicines to patients with cancer. Our heritage of science-based precision medicine and immuno-oncology means that we can branch into synergies to bridge different aspects of cancer research, in an agile and uncompromising manner. Our research focus is on three key mechanistic pillars: oncogenic pathways; immuno-oncology (IO); and DNA damage response (DDR); and, we are developing new approaches in key tumor types in GI, GU and thoracic cancers, all areas with significant unmet treatment needs. Together, we are transforming cancer care—today and tomorrow.
Sponsored Content by Tempus
Since the U.S. Food and Drug Administration (FDA) approval of DARZALEX® (daratumumab) in 2015, the first CD38-directed antibody to treat multiple myeloma has been used in the treatment of more than 68,000 patients in the U.S. alone.
As ongoing research continues to unlock the mechanisms of non–small cell lung cancer, it’s becoming increasingly clear that healthcare providers need to start rethinking how treatment is approached—especially for Stage 3 disease.
While great progress has been made in developing and delivering new treatment options for chronic lymphocytic leukemia, recognizing the chronic nature of the disease and being cognizant of side effects that can have a major impact on a patient’s quality of life remains an important responsibility.
Amgen Oncology is committed to investigating innovative approaches to fighting cancer, across both hematological malignancies and solid tumors.
Continued research is critical to potentially bring a targeted therapeutic option to patients with higher-risk myelodysplastic syndromes, to improve overall survival, manage symptoms, and preserve quality of life.
Two research papers presented by Roche and Foundation Medicine at the 2019 European Society of Medical Oncology (ESMO) Annual Meeting demonstrate both the promise of an innovative precision medicine driven clinical trial for patients with cancer of unknown primary, as well as the challenges of identifying eligible patients for the trial, according to ESMO guidelines.
Gary Fanjiang, MD, vice president of Biosimilars Global Development, Amgen, discusses the development of biosimilars and some of the clinical considerations related to their use.
New data presented at this year’s American Society of Hematology Annual Meeting showed that adding DARZALEX® (daratumumab) to standard of care multiple myeloma therapies may extend survival and achieve levels of minimal residual disease not previously seen.
Advancing cancer care requires more than just science. It’s a collective effort driven by passionate individuals and organizations dedicated to making a difference for those living with and affected by cancer.
Investigators are optimistic that LN-145, an autologous tumor-infiltrating lymphocyte investigational therapy, could be a potential treatment option for patients with recurrent, metastatic, or persistent cervical cancer.